Novo Nordisk expands GLP‑1 access, Medicare cuts noted

Novo Nordisk widened its latest U.S. access push for GLP-1 drugs in early May, adding a Medicare-specific Wegovy program and continuing direct-to-patient pharmacy offers that advertise lower cash prices on its own platform. The company said on May 7 that Wegovy access for Medicare beneficiaries living with obesity would expand through a “Medicare GLP-1 Bridge” beginning July 1. On NovoCare pages live this week, Novo also outlined how 2026 Medicare Part D costs work for Wegovy and separately promoted self-pay GLP-1 delivery offers through NovoCare Pharmacy. (novocare.com) (novonordisk.com) The move comes as semaglutide pricing pressure has intensified outside the United States. In India, semaglutide lost patent protection in March, opening the market to dozens of generic launches, while Bloomberg reported this month that Novo had already cut India prices and seen a sales increase there. ### What exactly did Novo Nordisk announce for Medicare patients? Novo Nordisk’s U.S. news archive lists a May 7 press release titled, “Wegovy access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026.” The company’s U.S. homepage also highlights that same announcement as one of its latest updates. (novonordisk-us.com) NovoCare’s Medicare page says Centers for Medicare & Medicaid Services coverage now includes obesity medicines such as Wegovy when they are approved by the FDA for another medical reason, giving cardiovascular risk reduction as the example. (fiercepharma.com) The page tells patients to compare Part D plans, seek a non-formulary exception if needed, and consider the Medicare Prescription Payment Plan to spread costs over the year. ### Where did the “$50 a month” claim come from? NovoCare’s Medicare materials reviewed on May 16 do not show a universal $50 monthly Wegovy price for all Medicare users. (novonordisk-us.com) The page instead lays out the standard 2026 Part D structure: a $615 deductible phase, then 25% coinsurance until a patient reaches $2,100 in out-of-pocket spending, and then $0 in the full-coverage phase. The same page says some patients in Medicare’s Extra Help program can face much lower branded-drug copays, including $12.65 in one subsidy tier and $4.90 in another, while full-benefit recipients can have no out-of-pocket prescription costs. (novocare.com) Any “$50 per month” figure circulating this week appears to be an inference from plan design, payment spreading, or subsidy examples rather than a blanket company-announced price on the Medicare page itself. ### How does this fit with Novo’s broader access strategy? NovoCare Pharmacy is advertising direct fulfillment for GLP-1 medicines with listed self-pay starting prices of $149 a month for certain Wegovy and Ozempic pill doses and $199 a month for certain pen doses for new patients, subject to eligibility and time limits. (novocare.com) The site says some introductory pen offers run through June 30 before rising to higher monthly prices. Novo Nordisk’s U.S. homepage and patient-support pages have increasingly grouped affordability, delivery and coverage tools together, including insurance navigation, pharmacy fulfillment and patient-assistance resources. (novocare.com) Those materials do not describe the effort as a market-share defense, but they show the company building more company-run access channels around branded GLP-1 products. ### Why are India and generic semaglutide part of this week’s discussion? March 20 was the date more than 40 Indian drugmakers were expected to begin launching semaglutide copies after patent expiry there, according to Fierce Pharma. (novocare.com) Bloomberg reported starter-dose generic prices as low as about 1,290 rupees, or roughly $14 a month, and said Novo had also cut branded prices in India. May 8 coverage from Bloomberg said Novo saw a 40% surge in India sales after those price cuts, even as generic GLP-1 medicines entered the market. (novonordisk-us.com) That overseas backdrop has been part of investor and analyst attention on how Novo is using pricing, pharmacy distribution and coverage support to keep branded semaglutide accessible in key markets. ### What should readers watch next? July 1, 2026 is the start date Novo Nordisk gave for the Medicare GLP-1 Bridge for Wegovy access expansion. (fiercepharma.com) August 5, 2026 is the date on Novo Nordisk’s investor calendar for its first-half 2026 financial results, the next scheduled company update likely to show how management describes uptake and access programs. (novonordisk-us.com) (bloomberg.com)